Warren Buffett has a record-high cash pile of $277bn. Should I stop investing?

Oliver Rodzianko, a Warren Buffett devotee, is assessing his own investing strategy as the legendary investor holds more cash than usual.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Warren Buffett would know if the US stock market was overvalued and due for a correction or crash. The fact that the Oracle of Omaha has been building his cash position, now at a record $277bn, could indicate that the valuation of many top American companies is currently unsustainable.

However, Buffett has also been securing Berkshire Hathaway’s legacy, including passing on the reins to new CEO-in-waiting Greg Abel. So, I think the big cash pile could be the investor’s way of allowing for flexibility and readiness for Abel’s tenure while preserving his remarkable track record.

Should I stop investing?

Firstly, I will never stop investing. I believe that there are always companies that the market is undervaluing and are worth my money, even in the hardest of times.

However, I also think that the valuation of the S&P 500, which is America’s most famous index, is potentially problematically high right now.

A lot of the recent growth has been in big tech firms. These include Nvidia, Alphabet, and Amazon‘s AI developments. The broader base of the 500 companies, on the other hand, has seen slower growth.


Created at TradingView

Nvidia alone has accounted for over a third of the S&P 500’s gains in 2024. Furthermore, analysts have noted that while the S&P 500 is projected to show 10% year-on-year earnings growth, this drops to just 6% when excluding the ‘Magnificent Seven’.

AI growth looks like it is going to slow down somewhat after a really bullish couple of years. So, I think the index could be in for a short-term correction.

Where should I look instead?

At the moment, I’m particularly fond of companies that have diversified well internationally. The Western markets are currently quite vulnerable to high inflation and contractions in GDP growth. However, India is now the highest growth nation in the world.

Thankfully, there are certain US-listed companies that operate in India. For example, Dr Reddy’s Laboratories (NYSE:RDY) has 17.5% of its revenue from India, 8% from Russia, and 26% from other countries. While the US is 48.5% of its total revenue base, the company still provides the good level of geographic diversification that I’m after.

Also, Dr Reddy’s has a decent valuation. Its price-to-earnings (P/E) ratio is 21, which is much lower than its 10-year median of 27. Furthermore, it has a robust three-year annual revenue growth of nearly 14% and earnings growth of 33%. So, I definitely consider this worthy of my watchlist.

However, investing in diverse markets comes with risks, especially in pharmaceuticals. A heavy concentration in India and Russia means that if policies and regulations change there, Dr Reddy’s could struggle to compete. It’s normal for global pharma companies to have to navigate diverse regulatory landscapes. However, Dr Reddy’s has concentrated more than Merck or Pfizer on specific non-Western countries, excluding China.

I’m diversifying

I’m looking to get away from some of the valuation risk and growth slowdown concerns in America. Buffett’s cash pile doesn’t mean that I should stop investing entirely. To me, it indicates a time to start assessing the risk in the US markets. After all, that’s where the investor has predominantly made his money. So, for now, I’m putting companies like Dr Reddy’s on my watchlist rather than Nvidia.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Oliver Rodzianko has positions in Alphabet and Amazon. The Motley Fool UK has recommended Alphabet, Amazon, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »